

## AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (October 2005), Supplement 2 (October 2005), and Supplement 3 (November 2005) are preceded, respectively, by S1:, S2:, and S3:.

- |                              |                            |  |
|------------------------------|----------------------------|--|
| Abbas, N.A., 610             | Berbarie, R.F., 1:li, 1:E1 | Centor, R.M., 595                      |
| Abbaterusso, C., 120         | Berthier-Schaad, Y., 78    | Chapman, A.B., 1058                    |
| Abbott, K.C., 720            | Bhagat, G., 780            | Charytan, C., 58                       |
| Abosaif, N.Y., 1038          | Bhimani, B., 3:1xi, 3:E31  | Chavers, B.M., 995                     |
| Abrahamov, A., 837           | Bianchi, S., 45            | Chen, H., 35                           |
| Acquistapace, I., 897        | Bidani, A., 587            | Chen, J.-R., 1099                      |
| Aguilera, A., 938            | Bigazzi, R., 45            | Chen, S.-T., 1099                      |
| Aguilera, I., 345            | Bihorac, A., 908           | Cheng, C.-H., 830                      |
| Akbostanci, M.C., 1:E13      | Binaut, R., 3:E41          | Cheung, A.K., 537, 577                 |
| Aldigier, J.-C., 6:E113      | Binik, Y.M., 1088          | Chi, E.M., 481                         |
| Algur, N., 837               | Bircher, G., 387           | Chiodini, P., 18                       |
| Aljama, P., 68               | Blank, G., 440             | Chiu, Y.-L., 2:E21                     |
| Allemand, H., 309            | Bleyer, A.J., 464          | Chonchol, M., 58                       |
| Allen, A.S., 642             | Boeschoten, E.W., 925      | Chou, S., 1117                         |
| Allison, J.J., 595           | Bökenkamp, S.I., 5:E71     | Chow, K.-M., 128, 713                  |
| Allon, M., 501               | Bolt, R.J., 5:1, 5:E71     | Christenson, R., 35                    |
| Alvarez-Lara, M.A., 68       | Bonforte, G., 897          | Chu, T.-S., 2:E21                      |
| Alves-Rodrigues, E.N., 4:E51 | Bos, W.J., 925             | Chung, K.-Y., 128                      |
| Ambühl, P., 529              | Boschi, G., 18             | Cianciaruso, B., 120                   |
| Andreucci, M.V., 120         | Bosi, A., 550              | Cirami, C., 550                        |
| Antoniadi, G., 706           | Bossola, M., 371           | Cirugeda, A., 938                      |
| Aranda, F.J., 1074           | Bosworth, H.B., 642        | Clase, C.M., 845                       |
| Aranda, P., 1074             | Braden, G.L., 560          | Coburn, J.W., 58                       |
| Arfè, G., 18                 | Bradley, J., 1117          | Coe, F.L., 263                         |
| Ariano, R.E., 681            | Brancati, C., 18           | Cohen, S.S., 863                       |
| Aroeira, L.S., 938           | Branten, A.J.W., 1012      | Cole, E., 529                          |
| Avorn, J., 225, 1080         | Brennan, D.C., 720         | Cole, E.H., 163                        |
| Axelsson, J., 628            | Brenner, R.M., 481         | Colindres, R.E., 812                   |
| Bae, K.T., 1058              | Breslau, N.A., 1:li, 1:E1  | Collins, A.J., 455, 481, 650, 661, 887 |
| Bailie, G.R., 669            | Brimhall, B.B., 1049       | Comotti, C., 120                       |
| Baird, B.C., 537             | Brown, E.A., 856           | Conte, G., 18                          |
| Bajo, M.A., 938              | Brown, S., 111             | Cooper, R., 587                        |
| Bammens, B., 512             | Buccianti, G., 897         | Coresh, J., 78, 203                    |
| Banet, J.F., 52              | Buhaescu, I., 173          | Cortese, C.M., 754                     |
| Bang, H., 812                | Buring, J.E., 871          | Cotsonis, G., 26                       |
| Bárány, P., 628              | Burkart, J., 464           | Coventry, S., 982                      |
| Barbutis, K., 706            | Burke, G.L., 214           | Covic, A., 173                         |
| Barker, J., 501              | Burroughs, T.E., 720       | Cowper, S.E., 763                      |
| Barre, P., 799               | Caldwell, S., 933          | Cox, J.L., 845                         |
| Barré, P.E., 1088            | Campese, V.M., 45          | Craig, J.C., 774, 970                  |
| Barrett, B., 799             | Canbakan, B., 1:E13        | Craven, T.E., 214                      |
| Barrio-Lucía, V., 52         | Cannella, C.A., 669        | Croker, B., 4:E55                      |
| Bastani, B., 754             | Cannella, G., 320          | Cross, A.S., 997                       |
| Bauer, E., 903               | Cao, G., 587               | Daar, E.S., 290                        |
| Bazari, H., 143              | Carey, H.B., 1:E5          | D'Agati, V., 780                       |
| Beck, G.J., 455              | Carlisle, E., 799          | Danese, M.D., 301                      |
| Becker, G.J., 990            | Carlsson, K., 1:E5         | Daniel, L., 3:E41                      |
| Becker, Y.T., 5:E91          | Carr, J.J., 464            | Daram, S.R., 754                       |
| Becker-Cohen, R., 837        | Carter, J.E., 351          | Davies, A.H., 856                      |
| Beddhu, S., 577              | Cassottana, P., 320        | Dean, B.B., 301                        |
| Bellino, D., 320             | Cavalcante, J.L., 270      | DeCristofaro, V., 897                  |

- Decruyenaere, J., 5:E95  
 Decupere, M., 5:E75  
 deFilippi, C.R., 35  
 Deighan, C.J., 1065  
 de Jong, P.E., 102  
 Dekker, F.W., 925  
 Delgado, P., 339  
 del Peso, G., 938  
 Demadura, T., 919  
 de Mutsert, R., 387  
 De Nicola, L., 18  
 Dennis, V.W., 242  
 de Oliveira Marques, F., 957  
 DeOreo, P.B., 621  
 Derfler, K., 446, 903  
 de Sa, D., 351  
 DeVecchi, A., 897  
 Devins, G.M., 1088  
 Dhondt, A., 5:E95  
 Diaconita, M., 6:E113  
 Diaz, F., 339  
 Dingli, D., 278  
 Dinits-Pensy, M., 997  
 Dionne, J.M., 351  
 Dipchand, C.S., 845  
 Dispenzieri, A., 270  
 Dixit, A., 3:xi, 3:E31  
 Djurdjev, O., 799  
 Dombek, S., 94  
 Don, B.R., 820  
 Druml, W., 903  
 Dubois, R.W., 301  
 du Buf-Vereijken, P.W.G., 1012  
 du Cailar, G., 233  
 Duff, D.R., 982  
 Dylan, M.L., 301  
  
 Ebben, J.P., 661  
 Edwards, M.S., 214  
 Ejaz, A.A., 4:E55  
 Ekong, E., 309  
 Eleftheriadis, T., 706  
 Elia, M., 387  
 Elinder, C.-G., 863  
 Ellis, M.R., 856  
 Ellison, D.H., 356  
 El Nahas, A.M., 1038  
 Eloit, S., 5:E95  
 Elstein, D., 837  
 Emmett, M., 1:ii, 1:E1  
 Engfer, M., 387  
 Ensari, A., 1:E13  
 Ergün, I., 1:E13  
 Ethier, J., 799  
 Evans, I.V., 1107  
 Evans, M., 863  
 Evenepoel, P., 512  
  
 Fain, P., 415  
 Faini, A., 897  
 Fakhouri, F., 3:E41  
  
 Falagas, M.E., 1030  
 Fallin, M.D., 78  
 Fan, Q., 661  
 Fanelli, F.R., 371  
 Feldman, H.I., 734  
 Fellström, B., 529  
 Fender, P., 309  
 Fenton, S.S.A., 136  
 Ferng, S.-H., 1099  
 Fervenza, F.C., 270  
 Fesler, P., 233  
 Fine, A., 681  
 Fink, J.C., 35  
 Fink, N.E., 78, 1107  
 Finkel, K.W., 26  
 Fischer, M.A., 1080  
 Fischer, M.J., 1049  
 Födinger, M., 520  
 Fogo, A.B., 2:liii, 2:E17, 573, 982  
 Foley, R.N., 995  
 Fontes, C.J.F., 4:E51  
 Fore, C.M., 863  
 Forman, J.P., 143  
 Forrest, G.N., 997  
 Fouque, D., 387  
 Fried, L.F., 214  
 Frishberg, Y., 837  
 Frutos, M.A., 1074  
 Fryzek, J.P., 863  
 Fujita, T., 4:E65  
  
 Gaber, L.W., 1140  
 Gage, B.F., 791  
 Ganai, A., 949  
 Ganzini, L., 919  
 Garganta, C.L., 1:E5  
 Gaziano, J.M., 871  
 Geddes, C.C., 949  
 Gelber, R.P., 871  
 Geneidy, A.A., 962  
 Genovesi, S., 897  
 Gentil, M.A., 345  
 Gertz, M.A., 270  
 Giannatos, E., 706  
 Giannico, G., 2:liii, 2:E17  
 Gilbertson, D.T., 887  
 Gillen, D.L., 263  
 Giungi, S., 371  
 Gjertson, D.W., 489  
 Glazner, J.E., 1049  
 Glickman, J.D., 316  
 Glynn, C., 1065  
 Gökden, N., 573  
 Goldfarb-Rumyantzev, A.S., 537  
 Gonzalez, A., 339  
 Gonzalez-Escribano, F., 345  
 Goshorn, J., 5:E81  
 Gourishankar, S., 1117  
 Grambow, S.C., 642  
 Grande, J.P., 278  
 Grantham, J.J., 1058  
  
 Greene, T., 242, 455  
 Greenland, S., 489  
 Griffiths, R.I., 301  
 Grisar, J., 520  
 Grönhagen-Riska, C., 529  
 Gross, E., 94  
 Grünfeld, J.-P., 3:E41  
 Guay-Woodford, L.M., 1058  
 Guidi, S., 550  
 Guo, H., 887  
 Gutierrez, P., 339  
  
 Ha, A., 86  
 Hadas-Halpern, I., 837  
 Hall, P.M., 242  
 Hansen, K.J., 214  
 Hara, S., 6:E103  
 Harries, S., 933  
 Hauser, A.-C., 446  
 Hauser, L., 446  
 Hayward, R.A., 406  
 Heap, M., 1038  
 Hedayati, S.S., 642  
 Hedican, S., 5:E91  
 Heeringa, P., 253  
 Heimbürger, O., 628  
 Hemmelgarn, B., 1117  
 Hemmi, N., 603  
 Herman, J., 58  
 Hernandez, D., 339  
 Hesse, A., 440  
 Higa, Y., 6:E103  
 Hirsch, D.J., 509  
 Hise, M.K., 997  
 Hofman, R.M., 5:E91  
 Hogan, S.L., 812  
 Holdaas, H., 529  
 Holland, D., 799  
 Hoppe, B., 440  
 Hor, L.-I., 432  
 Hörl, W.H., 446, 520  
 Hoshino, J., 6:E103  
 Houston, T.K., 595  
 Hsueh, P.-R., 2:E21  
 Huang, J.-J., 432  
 Huang, J.-W., 2:E21  
 Huisman, R.M., 102  
 Humphreys, B.D., 143  
 Hurdle, J.F., 537  
 Hylton, T.N., 11  
 Hyodo, T., 4:E59  
  
 Iaccarino, P., 18  
 Ikee, R., 603  
 Ikenoue, T., 4:E59  
 Ikizler, T.A., 976  
 Imakiire, T., 603, 4:E59  
 Irish, W., 720  
 Ishida, H., 688  
 Ishii, Y., 688  
 Izumi, T., 4:E59

- Jaffe, J.A., 316  
 Jardine, A.G., 529  
 Jassal, S.V., 136  
 Jensen, J.D., 470  
 Jhangri, G.S., 1117  
 Jiménez-Heffernan, J.A., 938  
 Jindal, K., 933  
 Joffe, M.M., 734  
 Joffy, S., 1  
 John, R.I., 610  
 Johnson, A.M., 415  
 Johnson, R.J., 4:E55  
 Joukhadar, C., 903  
 Juknis, H.I., 94  
 Jurkovitz, C., 11  
  
 Kadoguti, K., 6:E103  
 Kajbaf, S., 86  
 Kalantar-Zadeh, K., 290, 489  
 Kanai, H., 688  
 Kappel, J., 799  
 Karamperis, N., 470  
 Kasiske, B.L., 995  
 Katori, H., 6:E103  
 Kausz, A.T., 871, 887  
 Kawai, H., 688  
 Kazmi, W.H., 887  
 Keiran, S., 3:ixi, 3:E31  
 Kelleher, C.L., 1145  
 Kellerman, P.S., 746  
 Kelly, G., 111  
 Kempson, M.E., 610  
 Keough-Ryan, T.M., 845  
 Keven, K., 1:E13  
 Khoury, N., 1124  
 Kiberd, B.A., 845  
 Kiefe, C.I., 595  
 Kielstein, J.T., 186  
 Kikuchi, Y., 603, 4:E59  
 Kilpatrick, R.D., 489  
 Kimmel, P.L., 577  
 King, B.F., 1058  
 Kingma, H.A., 102  
 Kitahara, T., 688  
 Kitajima, I., 6:E103  
 Klag, M.J., 78  
 Klarenbach, S., 933  
 Klassen, P.S., 58  
 Klein, R., 214  
 Knebelmann, B., 3:E41  
 Ko, Y.-H., 432  
 Kobayashi, S., 603, 749  
 Koçer, B., 1:E13  
 Komatsuda, A., 2:E25  
 Kopp, C.W., 520  
 Kopple, J.D., 489  
 Korevaar, J.C., 925  
 Kortsaris, A., 706  
 Koyanagi, H., 688  
 Kramar, R., 424  
 Kramer, H., 587  
  
 Kraus, M.A., 4:xlvi, 4:E47, 967  
 Krediet, R.T., 925  
 Krishnan, M., 481  
 Kronenberg, F., 424  
 Kshirsagar, A.V., 812  
 Kulinskaya, E., 856  
 Kumar, J., 573  
 Kumar, V.A., 820  
 Kumasaka, R., 4:E65  
 Kuo, P.-W., 635  
 Kurth, T., 871  
 Kusano, E., 697  
 Kusek, J.W., 455  
 Kuypers, D.R.J., 5:E75  
 Kwan, B.C.-H., 128  
 Kyle, R.A., 278  
  
 Lacy, M.Q., 270  
 Lam, C.W.-L., 713  
 Lamb, E.J., 610  
 Larson, D.R., 278  
 Lasagni, L., 550  
 Lau, K.K., 1140  
 Laube, N., 440  
 Law, M.-C., 128  
 Lazarus, M., 481  
 Lazzeri, E., 550  
 Lee, H.-R., 1099  
 Lee, T., 501  
 Leitão, A.A., 957  
 Leite, C.A., 957  
 LeMeur, Y., 6:E113  
 Lens, X.M., 52  
 Lentine, K.L., 720  
 Lerut, E., 5:E75  
 Leung, C.-B., 128, 713  
 Leung, N., 270  
 Levey, A.S., 455, 871  
 Levin, A., 799  
 Levin, R., 1080  
 Levitski-Heikkilä, T.V., 6:E119  
 Levy, J., 173  
 Lezotte, D.C., 1049  
 Lhotka, K., 424  
 Li, L., 720  
 Li, P.K.-T., 128, 713  
 Li, Y.-J., 6:E125  
 Liakopoulos, V., 706  
 Libório, A.B., 957  
 Lien, Y.H., 58  
 Liftman, C., 316  
 Lin, C.-Y., 328  
 Lin, J.-L., 6:E125  
 Lin, M.-I., 635  
 Linas, S.L., 1145  
 Lindholm, B., 628  
 Lino, M., 3:E41  
 Liu, J., 661  
 Liu, W., 58  
 Liu, Y., 78  
 Lo, K.-Y., 5:E87  
  
 Lo, M.-w., 5:E87  
 Logan, J.O., 529  
 Lopez, V., 1074  
 López-Cabrera, M., 938  
 Lorenzo, V., 339  
 Love, T.E., 621  
 Luciani, G., 371  
 Luke, A., 587  
  
 Macdougall, I.C., 283  
 MacGregor, M.S., 1065  
 MacNeily, A.E., 351  
 Macron-Nogués, F., 309  
 Madsen, S., 529  
 Maes, B., 529  
 Maesato, K., 749  
 Magee, C.C., 143  
 Magner, P., 799  
 Mähr, N., 424  
 Mak, S.-K., 5:E87  
 Mange, K.C., 734  
 Manley, H.J., 669  
 Manson, J.E., 871  
 Markowitz, G.S., 780  
 Martin, P.C., 881  
 Martini-Filho, D., 4:E51  
 Martin-Malo, A., 68  
 Masai, R., 2:E25  
 Matsell, D., 351  
 Matsumoto, H., 697  
 Matsumoto, T., 688  
 Mayer, G., 424  
 Mazzinghi, B., 550  
 McAllister, C.J., 489  
 McCary, L.C., 58  
 McClellan, W.M., 11, 595  
 McGee, D., 587  
 McLaughlin, J.K., 863  
 Mendelssohn, D.C., 1088  
 Menon, V., 455  
 Mentari, E.K., 621  
 Merkin, S.S., 203  
 Meyer, K.B., 1107  
 Miller, J.P., 1058  
 Miller, L.G., 290  
 Mimran, A., 233  
 Minar, E., 520  
 Minutolo, R., 18  
 Miskulin, D.C., 557  
 Mitchell, R.L., 774  
 Miura, S., 603, 4:E59  
 Mogun, H., 225  
 Momose, A., 4:E65  
 Moriya, H., 603, 749  
 Morrison, K.B., 351  
 Mougnot, B., 1124  
 Muirhead, N., 799  
 Mukoyama, Y., 697  
 Mulhern, J.G., 560  
 Munjal, S., 4:E55  
 Murray, P.T., 26

- Muscaritoli, M., 371  
Muto, S., 697
- Nair, R., 362  
Nakamura, M., 4:E65  
Nakamura, N., 4:E65  
Namiki, S., 697  
Nanovic, L., 5:E91  
Nass, C.M., 35  
Nast, C.C., 1146  
Nef, P.C., 242  
Negishi, K., 749  
Nergizoglu, G., 1:E13  
Neumayer, H.-H., 529  
Newsome, B.B., 595  
Neyer, U., 424  
Nissenson, A.R., 301  
Njalsson, R., 1:E5  
Noël, L.-H., 3:E41  
Noguchi, T., 688  
Nojima, Y., 688  
Nomura, K., 6:E103  
Noordzij, M., 925  
Novaies, E.L. de, 1074  
Nuñez-Roldan, A., 345  
Nyberg, G., 529  
Nyrén, O., 863
- Obialo, C.I., 881  
Obrador, G.T., 650, 887  
O'Connor, A.S., 621, 766  
Ofili, E.O., 881  
Ofman, J.J., 481  
Ofsthun, N.J., 481  
Ohashi, M., 697  
Ohtake, T., 749  
Ohtani, H., 2:E25  
Ojo, A.O., 406  
Oka, M., 749  
Okamoto, K., 749  
Okumura, K., 4:E65  
Okuyama, S., 2:E25  
Olsson, A.G., 529  
O'Neill, W.C., 1058  
Ono, K., 688  
Ooms, V., 5:E75  
O'Reilly, K., 2:liii, 2:E17  
Osawa, H., 4:E65  
O'Shea, M.H., 560  
Outeda, P., 52  
Oyama, N., 4:E65
- Pabinger-Fasching, I., 446  
Pannu, N., 933  
Paoletti, E., 320  
Paraf, F., 6:E113  
Parikh, C., 1049, 1129  
Park, J., 791  
Pasquali, S., 120  
Patel, U.D., 406  
Patey, N., 3:E41
- Patrick, A.R., 225  
Pedersen, T., 529  
Pelle, G., 1124  
Peng, S.-J., 1099  
Perazella, M.A., 1129  
Pereira, A.A., 455  
Pereira, B.J.G., 887  
Pérez-Lozano, M.L., 938  
Perrone, R.D., 557  
Perry, E., 111  
Person, S.D., 595  
Peters, T.G., 760  
Piazza, M., 464  
Pichette, V., 58, 799  
Pisani, A., 120  
Plevak, M.F., 278  
Poggio, E.D., 242  
Pogliani, D., 897  
Porter, G.A., 988  
Powe, N.R., 203, 1107  
Praxedes, J.N., 957  
Preston, E., 856  
Price, C.P., 610  
Prischl, F., 424  
Procaccini, D., 120  
Puttinger, H., 520
- Quarshie, A., 881  
Quehenberger, P., 446  
Qureshi, A.R., 628
- Rabb, H., 967  
Rabel-Filho, O.C., 4:E51  
Raman, T., 1:E5  
Ramírez-Huesca, M., 938  
Ramkumar, N., 577  
Ratanjee, S.K., 3:E35  
Reijingoud, D.-J., 102  
Rerolle, J.-P., 6:E113  
Rexrode, S., 681  
Ribeiro, L.C., 4:E51  
Ribstein, J., 233  
Ricanati, E.S., 621  
Rietschel, E., 440  
Ristoff, E., 1:E5  
Riva, A., 897  
Robbin, M.L., 1058  
Roberts, T.L., 650  
Roche, A., 283  
Rodger, S.C., 949  
Roditi, G., 1065  
Rodriguez, M., 68  
Rodriguez-Benot, A., 68  
Rohr, M., 464  
Rolla, D., 320  
Romagnani, P., 550  
Rondeau, E., 1124  
Rose, C.L., 845  
Rosenberg, M.E., 995  
Rosner, M.H., 1  
Ross, E.A., 908
- Rossini, M., 573, 982  
Rothstein, M., 94  
Roux, A.V.D., 203  
Rudensky, B., 837  
Ruilopec, L.M., 1074  
Russell, G., 464  
Russell, J., 1038  
Rustin, P., 3:E41  
Rutgers, A., 253
- Sabbatini, M., 120  
Said, M., 362  
St. Peter, W.L., 650, 669  
Salanave, B., 309  
Salvadori, M., 550  
Sam, R., 6:lii, 6:E101  
Samuels, J., 26  
Sanchez, E., 339  
Sánchez-Tomero, J.A., 938  
Sarnak, M.J., 455  
Savoldi, S., 120  
Sawa, N., 6:E103  
Sawada, K.-i., 2:E25  
Scandling, J.D., 165, 537  
Schaller, G., 520  
Schaubel, D.E., 136  
Schelling, J.R., 766  
Schneeweiss, S., 225, 1080  
Schnitzler, M.A., 720  
Schrier, R.W., 415  
Schulman, G., 976  
Sebata, K., 697  
Segers, H., 5:E95  
Segura, J., 1074  
Sehgal, A.R., 621  
Seidinger, D., 520  
Seifter, J., 143  
Sekhon, I., 4:E55  
Sekihara, T., 688  
Selgas, R., 938  
Serpaggi, J., 3:E41  
Sethi, S., 159  
Shah, G.N., 5:1, 5:E71  
Shaw, A.D., 26  
Shimada, M., 4:E65  
Shinaberger, C.S., 489  
Shinohara, M., 688  
Shoham, D., 812  
Shoji, F., 697  
Shoker, A., 799  
Siddiqui, S., 1065  
Sidhu, H., 440  
Siegel, D.S., 780  
Signoriello, G., 18  
Silva, M.D., 4:E51  
Simpson, R.J., Jr., 812  
Singer, J., 799  
Sitar, D.S., 681  
Slot, M., 253  
Sloth, E., 470  
Sly, W.S., 5:1, 5:E71

- Smith, C., 949  
 Smith, D., 111  
 Smith, M.W., 78  
 Solid, C., 481  
 Solomon, D.H., 225  
 Soltys, G., 799  
 Spinelli, L., 120  
 Stafford, J., 214  
 Stechuchak, K.M., 642  
 Stefani, F., 897  
 Stefanidis, I., 706  
 Stegall, M.D., 974  
 Steiner, S., 520  
 Stella, A., 897  
 Stellaard, F., 102  
 Stenvinkel, P., 387, 628  
 Stratton, R.J., 387  
 Strippoli, G.F.M., 970  
 Stuccio-White, N., 481  
 Su, S., 635  
 Sunder-Plassmann, G., 520  
 Suwabe, T., 6:E103  
 Suzuki, S., 603, 4:E59  
 Swan, S.K., 995  
 Swartz, J., 111  
 Swartz, R., 111  
 Szczech, L.A., 642  
 Szelag, J.-C., 6:E113  
 Szeto, C.-C., 128, 713  
  
 Tagami, T., 6:E103  
 Tailor, P., 1:E5  
 Takaichi, K., 6:E103  
 Takemoto, F., 6:E103  
 Takiuchi, A., 4:E51  
 Tam, P., 799  
 Taub, K., 1088  
 Taylor, H. A., 203  
 Taylor, M., 415  
 Tazza, L., 371  
 Tervaert, J.W.C., 253  
 Testagrossa, L., 957  
 Thein, H., 3:E35  
 Thiard, B., 309  
 Thompson, C., 799  
 Thompson, K.J., 845  
 Thompson, P.A., 1058  
 Thornberry, J.M., 746  
 Tison, M., 415  
 Tobe, S., 799  
 Toderico, C., 18  
 Tolba, Y.A., 1038  
 Tonelli, M., 933, 1117  
 Tong, G. M.-W., 5:E85  
  
 Torres, A., 339  
 Torres, V.E., 1058  
 Tortorelli, A., 371  
 Toyoshima, I., 2:E25  
 Tracy, R.P., 78  
 Tsai, I.-J., 830  
 Tsai, J.J., 820  
 Tsao, L., 780  
 Tsau, Y.-K., 830  
 Tseng, C.-C., 432  
 Tsiaga, P., 706  
 Tsuchida, A., 688  
 Tumlin, J.A., 26  
  
 Ubara, Y., 6:E103  
 Ullian, M.E., 6:E119  
 Unruh, M.L., 1107  
  
 Valsecchi, M.G., 897  
 van Breda Vriesman, P., 253  
 Vandewoude, K., 5:E91  
 Vanhille, P., 3:E41  
 Vanholder, R., 5:E95  
 Van Lente, F., 242  
 van Paassen, P., 253  
 Vanrenterghem, Y., 512, 5:E75  
 Varaut, A., 3:E41  
 Vargemezis, V., 706  
 Vaseemuddin, M., 4:xlvi, 4:E47, 6:lii, 6:E101  
 Veeneman, J.M., 102  
 Veinot, J.P., 86  
 Verbeke, J.I.M.L., 5:1, 5:E71  
 Verbeke, K., 512  
 Vergidis, P.I., 1030  
 Verhave, J.C., 233  
 Vernay, M., 309  
 Verrelli, M., 799  
 Verstraete, A., 5:E95  
 Vickery, S., 610  
 Vijayan, A., 791  
 Villicana, R., 270  
 Vincenti, A., 897  
 von Unruh, G.E., 440  
 Vychytil, A., 520  
  
 Wadgyamar, J.A., 799  
 Wakui, H., 2:E25  
 Wang, H.-H., 328  
 Wang, J.-D., 635  
 Wang, M.-C., 432  
 Wang, P.-L., 919  
 Wang, P.S., 1080  
 Wang, X., 242, 455  
  
 Warnock, D.G., 595  
 Watanabe, H., 697  
 Watanabe, S., 2:E25  
 Watanabe, Y., 688  
 Watnick, S., 919  
 Webb, M.C., 610  
 Webster, A.C., 774  
 Weise, W.J., 962  
 Weissman, N.W., 595  
 Weng, F.L., 734  
 Wennick, J.M.B., 5:1, 5:E71  
 Wetzel, L.H., 1058  
 Wetzels, J.F.M., 1012  
 Wichmann, I., 345  
 Wiggins, J., 147  
 Wilson, D.B., 214  
 Winkelmayer, W.C., 225, 1080  
 Wolzt, M., 520  
 Wong, A.K.-M., 5:E87  
 Wong, P.-N., 5:E87  
 Wong, T.Y., 214  
 Wong, T.Y.-H., 713  
 Wong, Y., 5:E87  
 Worcester, E.M., 263  
 Wu, J.-J., 432  
 Wu, K.-D., 2:E21  
 Wyatt, R.J., 1140  
  
 Xu, Y., 1124  
  
 Yamabe, H., 4:E65  
 Yamada, T., 697  
 Yamamoto, Y., 697  
 Yang, C.-S., 1099  
 Yang, C.-W., 6:E125  
 Yang, S.-C., 635  
 Yeun, J.Y., 820  
 Yonekura, T., 697  
 Yoshizawa, N., 4:E59  
 Youell, T.D., 5:E81  
 Young, E.W., 406  
 Youssef, G.M., 509  
 Yu, C.-C., 6:E125  
 Yu, H.-T., 301  
  
 Zamboli, P., 18  
 Zandi-Nejad, K., 143  
 Zelenitsky, S.A., 681  
 Zeveloff, S., 780  
 Zimmerman, D., 86  
 Zimran, A., 837  
 Zoccali, C., 186  
 Zuidema, S., 933

## SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (October 2005), Supplement 2 (October 2005), and Supplement 3 (November 2005) are preceded, respectively, by S1:, S2:, and S3:.

- Aboriginal people, transplantation waiting list for hemodialysis, 1117-1123
- Access to care, medical evaluation completion rates for renal transplantation, 734-745
- Acetaminophen, induction of anion gap metabolic acidosis, 143-146
- Acetylsalicylic acid, outcomes for acute coronary syndrome with chronic renal insufficiency, 845-855
- Acid-base balance, citrate kinetics in long-term hemodialysis, 903-907
- Acute coronary syndrome, with chronic renal insufficiency, outcomes for, 845-855
- Acute renal failure (ARF)
  - critically ill patients, erythropoietin for, 791-798
  - with diabetes mellitus and massive proteinuria, 362-366
  - erythropoietin therapy during, 791-798, 967-969
  - glucose metabolism in, 367-368(c)
  - induced by Brazilian variety of propolis, 6:E125
  - laboratory-performed vs. nephrologist-performed urinalysis, 820-829
  - with malignant hypertension and intestinal ischemia secondary to juxtaglomerular cell tumor, 957-961
  - in older patients, 149
  - outcome in ICU according to RIFLE, 1038-1048
  - randomized controlled trials, Cochrane Renal Group Report on, 774-779
  - in renal allograft, 159-162
- uncomplicated, hospital resource utilization and, 1049-1057
- Acute tubular necrosis (ATN)
  - with disseminated histoplasmosis and thrombotic microangiopathy, 159-162
  - early, fenoldopam for, 26-34
- Adequacy of dialysis
  - Medicare reimbursement changes and, 621-627
  - prevention of malnutrition in hemodialysis, 371-386
- ADPK. *See* Autosomal dominant polycystic kidney disease
- Advance directives for long-term dialysis patients, peer mentoring effects on, 111-119
- Adverse events, from iron sucrose as 2-minute push in CKD, 283-289
- African Americans. *See also* Race; Racial disparity
  - family history of ESRD, risk perception of kidney disease and, 11-17
  - peer mentoring effect on end-of-life decision making for long-term dialysis patients, 111-119
- Age
  - of recipient, allocation of deceased donor kidneys and, 949-956
  - renal function estimation in subjects with normal serum creatinine, 233-241
- Alcohol poisoning, validation of method for predicting required dialysis time for, 509-511
- Aldosterone, in oligo-anuric hemodialysis patients, spironolactone effect on, 94-101
- Aldosterone receptor antagonists, proteinuria reduction in CKD and, 45-51
- ALERT study, renal transplantation cardiovascular disease risk, 529-536
- Allograft
  - acute renal failure in, 159-162
  - graft-versus-host disease after allogeneic stem cell transplantation, 550-556
  - intolerance syndrome, incidence/efficacy of percutaneous embolization for, 339-344
  - pretransplantation RRT effect on survival, 537-549
  - rejection, MPGN-like injury pattern in, 573-576
- Alloimmune response, against GSTT1 antigen in renal transplant recipients, 345-350
- Aluminum
  - elevation frequency in adult dialysis patients, 316-319
  - toxicity, in pediatric chronic kidney disease, S1:70-86
- Alzheimer disease, in older patients, 153
- Amino-terminal proBNP, and B-type natriuretic peptide in CKD, 610-620
- Amyloidosis, due to tubulointerstitial nephritis in Sjögren syndrome, 5:E75
- Anaritide (atrial natriuretic peptide), in ESRD, 1-10
- ANCAs. *See* Antineutrophil cytoplasmic antibodies
- Anemia
  - darboepoetin alfa in renal transplant recipient during pregnancy, 5:E81
- erythropoietin
  - for critically ill patients with ARF requiring RRT, 791-798
  - prescribing patterns and hemoglobin outcomes in ESRD, 481-488
  - to prevent LV hypertrophy in CKD, 799-811
  - sensitivity in ESRD, influence of body fat mass and leptin levels on, 628-634
- hemoglobin target, debate over, 970-973
- IV iron usage trends in dialysis patients, 650-660
- outcomes for acute coronary syndrome with chronic renal insufficiency, 845-855
- in primary glomerular disease, 424-431
- quality of care, Medicare reimbursement changes and, 621-627
- Angioplasty, shorter unassisted patency of vascular access in women after, 167(c)
- Angiotensin, spironolactone effect on oligo-anuric hemodialysis patients, 94-101
- Angiotensin-converting enzyme inhibitors



- with aldosterone receptor antagonists for proteinuria reduction in CKD, 45-51
- underusage in elderly diabetics, 1080-1087
- Angiotensin receptor blockers (ARBs)
  - with aldosterone receptor antagonists for proteinuria reduction in CKD, 45-51
  - renoprotective effects of standard vs. high doses in hypertensive nondiabetic nephropathies, 1074-1079
  - underusage in elderly diabetic patients, 1080-1087
- Anion gap metabolic acidosis
  - acetaminophen-induced and 5-oxoprolinuria acquired in hospital, 143-146
  - recurrent high, secondary to 5-oxoproline, 1:E1
- Ankle-brachial blood pressure index, impact on hemodialysis mortality, 688-696
- ANP (atrial natriuretic peptide), in ESRD, 1-10
- Anticardiolipin antibodies, during immunoadsorption therapy, 446-454
- Anticoagulation
  - citrate kinetics in long-term hemodialysis therapy, 903-907
  - CVVH with citrate-based replacement fluid, 908-918
- Anti-glomerular basement membrane antibodies, with ANCA in crescentic glomerulonephritis, 253-262
- Anti-glomerular basement membrane disease, in diabetic nephropathy, 362-366
- Anti-glutathione S-transferase T1 antibodies, in renal transplant recipients, 345-350
- Antihypertensives, for CKD-related hypertension, 18-25
- Antilipoarabinomannan antibody (anti-LAM), diagnosis of latent tuberculosis in hemodialysis patients, 706-712
- Antineutrophil cytoplasmic antibodies (ANCA)
  - myeloperoxidase-specific, with anti-GBM antibodies in crescentic glomerulonephritis, 253-262
  - in systemic vasculitis, 173-185
- Antithymocyte globulin, for systemic vasculitis, 173-185
- APACHE II, acute renal failure outcome in ICU, 1038-1048
- Apolipoprotein, soy protein effects on hyperlipidemic and normolipidemic hemodialysis patients, 1099-1106
- ARF. *See* Acute renal failure
- ARIC (Atherosclerosis Risk in Communities Study), area socioeconomic status and progressive CKD, 203-213
- Arteriosclerosis. *See* Atherosclerosis
- Arteriovenous access
  - blood flow evaluation by optodilutional and ultrasound dilution methods, comparison of, 933-937
  - thrombosis, hyperhomocysteinemia and, 993-994 (letter)
  - usage in adult in-center hemodialysis patients, S2:21-39
- Assessment, geriatric, 151
- Asymmetric dimethylarginine, as cardiovascular risk factor in ESRD, 186-202
- Atherosclerosis
  - relationship of resistive index in damaged kidneys, 603-609
  - renal artery disease diagnosed by MRA, outcome prediction for, 1065-1073
- Atherosclerosis, impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on HD mortality, 688-696
- Atherosclerosis Risk in Communities Study (ARIC), area socioeconomic status and progressive CKD, 203-213
- ATN. *See* Acute tubular necrosis
- Atrial fibrillation, prevalence and associated factors in long-term hemodialysis patients, 897-902
- Atrial natriuretic peptide (ANP; anaritide), in ESRD, 1-10
- Autosomal dominant glomerulocystic kidney disease, novel mutation pattern in, 52-57
- Autosomal dominant medullary cystic kidney disease type 2 (MCKD2), novel mutation pattern in, 52-57
- Autosomal dominant polycystic kidney disease (ADPKD)
  - family history diagnosis implications for cardiovascular and renal complications, 415-423
  - hypertension in individuals at risk for, 557-559
  - pelvic insufficiency fracture and, 6:E101
  - sonographic assessment of severity and progression, 1058-1064
- Azathioprine, for systemic vasculitis maintenance therapy, 173-185
- Bacteria. *See also specific bacteria*
  - multiple rare environmental peritonitis in long-term peritoneal dialysis patient, 6:E119
- $\beta$ -Blockers, outcomes for acute coronary syndrome with chronic renal insufficiency, 845-855
- Bicarbonate turnover, in long-term hemodialysis, 102-110
- Biliary atresia, reversibility of nephromegaly in, 830-836
- Biopsy
  - of crescentic glomerulonephritis in diabetic nephropathy, 362-366
  - relationship of resistive index to atherosclerosis in damaged kidneys, 603-609
- Blacks. *See* African Americans; Race; Racial disparity
- Bladder substitution, urinary tract infections and, 1030-1037
- Bleeding risk
  - citrate-based replacement fluid for CVVH and, 908-918
  - thrombolytic-associated, delay in time receipt among Medicare patients with kidney disease, 595-602
- Blood pressure. *See also* Hypertension
  - in oligo-anuric hemodialysis patients, spironolactone effect on, 94-101
- Blood urea nitrogen, ratio with serum creatinine in estimating GFR in ill hospitalized patients, 242-252
- BMI. *See* Body mass index
- BNP. *See* B-type natriuretic peptide
- Body fat mass, erythropoietin sensitivity in ESRD and, 628-634
- Body fluids, composition of, 356-357
- Body mass index (BMI)
  - chronic kidney disease risk and, 871-880
  - natural history of chronic renal failure and, 863-870
  - nephrolithiasis and increased blood pressure in females and, 263-269
  - renal function estimation in subjects with normal serum creatinine and, 233-241
- Body weight change, effect on cardiovascular survival of hemodialysis patients, 489-500
- Bolus injection of iron sucrose, as 2-minute push in CKD, 283-289

- Bone**  
 formation and modeling, S1:8-9  
 mineral accretion, in CKD, S1:10-11
- Bone disease**  
 asymmetric dimethylarginine accumulation and, 186-202  
 in pediatric chronic kidney disease  
 assessment of, S1:18-22  
 clinical manifestations of, S1:9  
 treatment of, S1:87-90  
 in pediatric kidney transplant recipient, S1:96-98
- Bone morphogenic proteins in ESRD** valvular calcifications, compared with general population, 86-93
- Book reviews**  
*Chronic Kidney Disease, Dialysis, and Transplantation: A Companion to Brenner and Rector's The Kidney (Second Edition)*, 990-991  
*Diagnostic Atlas of Renal Pathology: A Companion to Brenner and Rector's Kidney (Seventh Edition)*, 1146-1147  
*Handbook of Kidney Transplantation (Fourth Edition)*, 163-164  
*Hypertension: A Companion to Brenner and Rector's The Kidney (Second Edition)*, 988-989  
*Medical Management of Kidney Transplantation*, 165-166  
*Primer on Kidney Disease (Fourth Edition)*, 1145
- Brachial-ankle pulse wave velocity, hemodialysis mortality and**, 688-696
- B-type natriuretic peptide (BNP; nesiritide)**  
 in ESRD, 1-10  
 N-terminal pro-B type  
 in CKD, 610-620  
 prediction of cardiac disease in asymptomatic CKD, 35-44
- Calcifications, cardiovascular**  
 changes after parathyroidectomy, 464-469  
 histological comparison with general population, 86-93
- Calcineurin inhibitors, thrombotic microangiopathy in patients receiving marginal kidneys**, 1124-1128
- Calcium**  
 citrate kinetics in long-term hemodialysis therapy and, 903-907  
 in coronary artery in ESRD, changes after parathyroidectomy, 464-469  
 coronary artery scores in ESRD, changes after parathyroidectomy, 464-469  
 in dialysate, in pediatric chronic kidney disease, S1:64-67  
 KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925-932  
 metabolism, evaluation in pediatric CKD, S1:12-17  
 in pediatric chronic kidney disease, S1:39-47
- Calcium-phosphorus product**  
 chronic kidney disease mortality and, 455-463  
 KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925-932  
 in pediatric chronic kidney disease, S1:39-47
- Calorimetry of energy expenditure, malnutrition in hemodialysis patients and**, 102-110
- Canada**  
 chronic renal insufficiency outcomes of acute coronary syndrome in, 845-855  
 randomized trial of hemoglobin maintenance to prevent LVH in CKD, 799-811
- CAPD. See Continuous ambulatory peritoneal dialysis**
- Carbon dioxide expiration, in long-term hemodialysis**, 102-110
- Cardiovascular calcifications. See Calcifications, cardiovascular**
- Cardiovascular disease**  
 atrial fibrillation prevalence in long-term hemodialysis, 897-902  
 with chronic renal insufficiency, outcomes for, 845-855  
 hypokalemia in Chinese peritoneal dialysis patients and, 128-135  
 mineral metabolism abnormalities and chronic kidney disease mortality, 455-463
- risk**  
 $\beta$ -fibrinogen haplotypes in dialysis patients and, 78-85  
 coronary artery intima-media thickness and chronic kidney disease, 856-862  
 in ESRD, asymmetric dimethylarginine and, 186-202  
 in peritoneal dialysis patients with ESRD, endothelial progenitor cells and, 520-528  
 renal transplantation and, 529-536
- Cardiovascular Health Study, renal function changes and renal microvascular abnormalities in elderly**, 214-224
- Cardiovascular mortality**  
 dialysis access-related infections and, 1149  
 effect of morbid obesity and weight change in hemodialysis patients, 489-500  
 hypokalemia in Chinese peritoneal dialysis patients and, 128-135
- Catheters**  
 bacteremia in coronary artery bypass graft of dialysis patient, 962-966  
 tethered with retained portions in central vein and right atrium on attempted removal, 3:E35  
 tunneled, in hemodialysis, 501-508
- Charlson Comorbidity Index (CCI), in measuring baseline comorbidity of kidney transplant patients**, 136-142
- Children. See also Pediatric chronic kidney disease**  
 with biliary atresia, reversibility of nephromegaly in, 830-836  
 in-center hemodialysis, clinical performance measures for, S2:47-57  
 purpura followed by proteinuria in, 1140-1144
- Chinese patients on peritoneal dialysis, hypokalemia in**, 128-135
- Chlorambucil, for idiopathic membranous nephropathy**, 1012-1029
- Cholesterol**  
 reduction  
 cardiovascular disease risk, renal transplantation and, 529-536  
 with cholestyramine, effect on renal function, 812-819  
 outcomes for ACS with chronic renal insufficiency, 845-855  
 of soy protein effects on hyperlipidemic hemodialysis patients, 1099-1106



- Cholesterol embolism, atherosclerotic renal artery disease diagnosed by MRA, outcome prediction for, 1065-1073
- Chronic kidney disease (CKD). *See also* Pediatric chronic kidney disease
- administration of IV iron sucrose as 2-minute push, 283-289
  - asymptomatic, NT-proBNP elevation in, 35-44
  - atherosclerotic diagnosed by MRA, outcome prediction for, 1065-1073
  - benefits of multnutrient support for maintenance dialysis patients, 387-405
  - cardiovascular risk, asymmetric dimethylarginine and, 186-202
  - coronary artery intima-media thickness and, 856-862
  - erythropoietin therapy for LV hypertrophy prevention, 799-811
  - hypertension management in primary and tertiary care, 18-25
  - inflammation in, metabolic syndrome and, 577-586
  - kidney transplantation waiting list for Aboriginal hemodialysis patients, 1117-1123
  - manganese-induced Parkinsonism in maintenance hemodialysis patient, 749-753
  - mortality, relationship of phosphorus and calcium-phosphorus product in, 455-463
  - nondiabetic predialysis patients, left ventricular hypertrophy in, 320-327
  - outcomes of acute coronary syndrome in, 845-855
  - patient opinions on allocation of deceased donor kidneys for transplantation, 949-956
  - predialysis cinacalcet therapy for secondary parathyroidism, 58-67
  - prevalence of left ventricular hypertrophy in, 1148-1149(c)
  - progression
    - mortality in elderly diabetics and, 406-414
    - socioeconomic status and, 203-213
  - retinal microvascular abnormalities in elderly and, 214-224
  - spironolactone reduction of proteinuria in, 45-51
  - survival extended by predialysis psychoeducational intervention, 1088-1098
  - vaccines for adult patients with, 977-1011
- Chronic proteinuric renal diseases, telmisartan standard vs. high doses in hypertensive nondiabetic nephropathies, 1074-1079
- Chronic renal failure (CRF)
- with abnormal tubular cells in siblings, 982-987
  - erythropoietin sensitivity, influence of body fat mass and leptin levels on, 628-634
  - erythropoietin therapy and, 967-969
  - natural history of, 863-870
- Cinacalcet, for secondary parathyroidism in predialysis CKD, 58-67
- Cirrhosis, primary biliary with Fanconi syndrome and tubulointerstitial nephritis, 3:E41
- Citrate kinetics, in long-term hemodialysis therapy, 903-907
- Clinical laboratory-performed urinalysis, compared with nephrologist-performed urinalysis, 820-829
- Cochrane Renal Group Report, of randomized controlled trials, 774-779
- Cockcroft-Gault equation
- in normal serum creatinine subjects, influence of age and body mass index on, 233-241
  - in estimating GFR in ill hospitalized patients, 242-252
- Cohort studies,  $\beta$ -fibrinogen haplotypes, cardiovascular disease risk in dialysis patients and, 78-85
- Comorbidity
- baseline, in renal transplant recipients, 136-142
  - hypokalemia in Chinese peritoneal dialysis patients and, 128-135
  - increased mortality associated with early initiation of dialysis and, 887-896
  - medication-related problems in hemodialysis patients, 669-680
- Compliance, incident hemodialysis and survival, 1107-1116
- Congestive heart failure, de novo, after kidney transplantation, 720-723
- Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP), sonographic assessment of severity and progression of AKPKD, 1058-1064
- Continuing medical education credit, for peer review of manuscripts, 995-996
- Continuous ambulatory peritoneal dialysis (CAPD)
- hypokalemia in Chinese patients, 128-135
  - peritonitis due to *Salmonella enteritis* in SLE patient, 2:E21
  - Vibrio vulnificus* peritonitis after handling seafood, 5:E87
- Continuous venovenous hemofiltration (CVVH), with citrate-based replacement fluid, 908-918
- Coronary artery bypass graft, mycotic aneurysms in dialysis patient, 962-966
- Coronary artery calcium, in ESRD, changes after parathyroidectomy, 464-469
- Coronary artery disease prediction, in asymptomatic CKD, 35-44
- Coronary artery intima-media thickness, chronic kidney disease and, 856-862
- C-reactive protein (CRP)
- cutoff point and clinical applicability, 368-369(c)
  - in diabetic peritoneal dialysis patients, rosiglitazone reduction of, 713-719
  - erythropoietin sensitivity in ESRD, influence of body fat mass and leptin levels on, 628-634
  - inflammation in CKD, metabolic syndrome and, 577-586
- Creatinine, serum
- chronic kidney disease progression in elderly diabetics and, 406-414
  - in identifying chronic kidney disease from Medicare claims data, 225-232
  - ratio with BUN in estimating GFR in ill hospitalized patients, 242-252
- Crescentic glomerulonephritis
- coexistence of ANCA and anti-GBM antibodies in, 253-262
  - with diabetic nephropathy, 362-366
- p*-Cresol, renal clearance time for incident peritoneal dialysis patients, 512-519

- CRISP (Consortium of Renal Imaging Studies in Polycystic Kidney Disease), sonographic assessment of severity and progression of AKPKD, 1058–1064
- CRP. *See* C-reactive protein
- Cryptococcosis, intracranial granuloma with skull osteolysis as complication in kidney transplant recipient, 6:E113
- C-type natriuretic peptide, in ESRD, 1–10
- Cyclophosphamide  
for idiopathic membranous nephropathy, 1012–1029  
for systemic vasculitis, 173–185
- Cyclosporine, for systemic vasculitis, 173–185
- Cystic fibrosis, absorptive hyperoxaluria leads to increased risk of urolithiasis and nephrocalcinosis in, 440–445
- Cytokines, in HCV infection in maintenance hemodialysis, 290–300
- Dapsone, renal hypersensitivity vasculitis associated with, 4:E51
- Darbepoetin alfa, for post-renal transplantation anemia during pregnancy, 5:E81
- Databases, utility of using Medicare claims data in identifying chronic kidney disease, 225–232
- Decisional capacity/competence, in older patients, 151
- Delirium, in older patients, 152
- Dementia  
asymmetric dimethylarginine accumulation and, 186–202  
in older patients, 153–154
- Demographic factors, hospital resource utilization for uncomplicated acute renal failure and, 1049–1057
- Deoxyspergualin, for systemic vasculitis, 173–185
- Depression  
in long-term hemodialysis, hospitalization risk and, 642–649  
in older patients, 152–153  
validation of depression screening tools in dialysis, 919–924
- Diabetes mellitus  
family history of ESRD, risk perception of kidney disease and, 11–17  
kidney and, nephrology core curriculum, 766–773  
with massive proteinuria and acute renal failure, 362–366  
predisposition to emphysematous pyelonephritis and, 432–439  
rosiglitazone effect on insulin requirements and CRP in PD patients, 713–719  
underuse of ACE inhibitors and ARBs in elderly patients, 1080–1087
- Diabetic nephropathy  
with crescentic glomerulonephritis, 362–366  
randomized controlled trials, Cochrane Renal Group Report on, 774–779
- Diagnosis  
of ADPKD, role of family history and implications for cardiovascular and renal complications, 415–423  
of chronic GVHD after allogeneic stem cell transplantation, 550–556  
of crescentic glomerulonephritis in diabetic nephropathy, 362–366  
hepatitis C virus, discordance in hemodialysis, 992(letter), 993(reply)
- of latent tuberculosis in hemodialysis, value of anti-LAM antibody for, 706–712
- Dialysate  
calcium concentrations, in pediatric chronic kidney disease, S1:64–67  
frequency of elevated serum aluminum in adult dialysis patients and, 316–319  
IL-12 and IL-18 levels in effluent, peritonitis outcome and, 328–338
- Dialysis. *See also* Hemodialysis; Peritoneal dialysis  
early initiation, effect of comorbidity on increased mortality of, 887–896  
erythropoietin for ARF patients and, 791–798  
for ESRD in France in 2003, prevalence of, 309–325  
with Fabry disease, effect of enzyme replacement therapy for, 120–127  
fenoldopam for early acute tubular necrosis and, 26–34  
frequency of elevated serum aluminum in adult patients, 316–319  
hospital resource utilization for uncomplicated acute renal failure, 1049–1057  
intravenous iron use trends, 650–660  
kidney transplantation waiting list for Aboriginal hemodialysis patients, 1117–1123  
late referral, socioeconomic implications of, 881–886  
natriuretic peptides in, 1–10  
randomized controlled trials, Cochrane Renal Group Report on, 774–779  
vaccines for adult chronic kidney disease patients, 997–1011  
validation of depression screening tools in, 919–924
- Dialysis time, validation of method for predicting for methanol and ethylene glycol poisoning, 509–511
- Dialyzer reuse, mortality, incident hemodialysis and, 661–668
- Direct costs, hospital resource utilization, uncomplicated acute renal failure and, 1049–1057
- Diuretics, for chronic kidney disease-related hypertension, 18–25
- Donor kidneys  
deceased, allocation for transplantation in CKD, 949–956  
marginal, thrombotic microangiopathy after sirolimus use, 1124–1128
- Doppler ultrasound, relationship of resistive index with arteriosclerosis in damaged kidneys, 603–609
- Dosing regimen  
adequacy in high-flux hemodialysis, 681–687  
V iron sucrose as 2-minute push for CKD patients, 283–289
- Echocardiography, atrial fibrillation prevalence in long-term hemodialysis, 897–902
- Economic outcomes, of *S. aureus* septicemia in ESRD patients on hemodialysis, 301–308
- Elderly patients  
with chronic of kidney disease and diabetes, progression and mortality in, 406–414  
with diabetes, underuse of ACE inhibitors and angiotensin II receptor blockers in, 1080–1087  
geriatrics nephrology core curriculum, 147–158

- retinal microvascular abnormalities in, renal function changes and, 214-224
- Emphysematous pyelonephritis predisposition, host and bacterial virulence factors in, 432-439
- Endocrine alterations, asymmetric dimethylarginine accumulation and, 186-202
- End of life care  
decision making for long-term dialysis, peer mentoring effect on, 111-119  
for older patients, 157-158
- Endothelial progenitor cells, cardiovascular disease history in peritoneal dialysis patients with ESRD, 520-528
- End-stage renal disease (ESRD)  
asymmetric dimethylarginine as cardiovascular risk factor in, 186-202  
 $\beta$ -fibrinogen haplotypes and CVD risk in dialysis patients, 78-85  
cardiovascular disease history in PD patients, endothelial progenitor cells and, 520-528  
changes in cardiovascular calcification after parathyroidectomy, 464-469  
clinical/economic outcomes of *Staphylococcus aureus* septicemia, 301-308  
clinical performance measures project, S2:1-100  
comorbidity effect on increased mortality associated with early initiation of dialysis, 887-896  
depression associated with long-term hemodialysis, hospitalization risk and, 642-649  
end-of-life decision making, peer mentoring effect on, 111-119  
epoetin alfa prescribing patterns and hemoglobin outcomes, 481-488  
erythropoietin sensitivity, influence of body fat mass and leptin levels on, 628-634  
incident hemodialysis, reuse-associated mortality and, 661-668  
mortality risk in hemodiafiltration and, 167-168(c)  
natriuretic peptides in, 1-10  
nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis in, 754-759  
oligo-anuric hemodialysis patients, spironolactone effects on, 94-101  
quality of care, Medicare reimbursement changes and, 621-627  
quality of life in HD patients measured by WHOQOL-BREF(TW), 635-641  
risk perception of, 11-17  
treated with renal dialysis, prevalence in France in 2003, 309-315  
valvular calcifications, histological comparison with general population, 86-93
- Energy expenditure, in long-term hemodialysis, 102-110
- Enteral nutrition benefits, for CKD maintenance dialysis patients, 387-405
- Enzyme HCV immunoassay, low sensitivity in maintenance hemodialysis patients, 290-300
- Enzyme replacement therapy for Fabry disease, effect on quality of life and organ involvement, 120-127
- Eosinophilia in atherosclerotic renal disease, outcome prediction for, 1065-1073
- EPO. *See* Erythropoietin
- Epoetin alfa in ESRD, recent prescribing patterns and hemoglobin outcomes, 481-488
- Epstein-Barr virus, renal leiomyoma in pediatric transplant patient and, 351-355
- Equity of access, allocation of deceased donor kidneys for transplantation, 949-956
- Erythropoietin (EPO)  
during acute kidney disease, 967-969  
for critically ill patients with ARF requiring renal replacement therapy, 791-798  
in ESRD  
recent prescribing patterns and hemoglobin outcomes, 481-488  
sensitivity influenced by body fat mass and leptin levels, 628-634  
optimal hemoglobin target, debate over, 970-973  
to prevent LV hypertrophy in CKD, 799-811
- Escherichia coli* gas production, predisposition to emphysematous pyelonephritis and, 432-439
- ESRD Clinical Performance Measures Project, 2004 annual report, S2:4-100
- Etanercept, for systemic vasculitis, 173-185
- Ethylene glycol poisoning, validation of method for predicting required dialysis time for, 509-511
- Extramedullary hematopoiesis, in multiple myeloma, 780-786
- Fabry disease dialysis patients, effect of enzyme replacement therapy for, 120-127
- Falls, in older patients, 154-155
- Familial juvenile hyperuricemic nephropathy, novel mutation pattern in, 52-57
- Family history of ESRD, race and, 11-17
- Fanconi syndrome, and tubulointerstitial nephritis in primary biliary cirrhosis, 3:E41
- Females  
allocation of deceased donor kidneys for transplantation, 949-956  
natural history of chronic renal failure and, 863-870  
nephrolithiasis and increased blood pressure with high BMI, 263-269  
proteinuria and Hgb levels in primary glomerular disease, 424-431  
shorter unassisted patency of vascular access after angioplasty, 167(c)
- Fenoldopam mesylate, for early acute tubular necrosis, 26-34
- Ferric gluconate, intravenous usage trends in dialysis patients, 650-660
- Fetal loss, anticardiolipin antibodies during immunoadsorption therapy and, 446-454
- $\beta$ -Fibrinogen haplotypes, risk of cardiovascular disease in dialysis cohort and, 78-85
- Fibrosis, with nephrogenic fibrosing dermopathy, 754-759
- Fistula, tunneled catheters in hemodialysis patients, 501-508
- Focal and segmental glomerulosclerosis, plasma cell disorders and, 278-282
- Frailty, of older patients, 156
- France, prevalence of ESRD treated with renal dialysis in 2003, 309-315

- $\alpha$ -Galactosidase A for Fabry disease, effect on quality of life and organ involvement, 120-127
- Gaucher disease, comprehensive renal function assessment in, 837-844
- Gender. *See* Females; Males
- Genius® Batch Hemodialysis System, efficiency with low serum solute concentrations, 5:E95
- Genotype mismatch, alloimmune response against GSTT1 in renal transplant recipients, 345-350
- Geriatrics, nephrology core curriculum, 147-158
- GFR. *See* Glomerular filtration rate
- Glomerular disease, in older patients, 149-150
- Glomerular filtration rate (GFR)  
estimation  
in ill hospitalized patients, 242-252  
in subjects with normal creatinine levels, effect of age and BMI on, 233-241  
in identifying chronic kidney disease from Medicare claims data, 225-232
- Glomerular hyperfiltration in Gaucher disease, renal function and, 837-844
- Glomerular tip lesions, nonsteroidal anti-inflammatory drug-induced nephrotic syndrome and, 4:E55
- Glomerulitis, acute transplant, MPGN-like injury pattern in, 573-576
- Glomerulonephritis  
crescentic  
coexistence of ANCA and anti-GBM antibodies in, 253-262  
with diabetic nephropathy, 362-366  
hepatitis C virus-associated without hepatitis C virus in blood, 4:E65  
poststreptococcal, complicated by hemolytic uremic syndrome and nephrotic syndrome, 4:E59  
proteinuria and hemoglobin levels in, 424-431
- Glucose metabolism, in early renal failure, 367-368(c)
- Glutathione, depletion of liver stores in acetaminophen-induced anion gap acidosis, 143-146
- Graft. *See* Allograft
- Graft intolerance syndrome, incidence/efficacy of percutaneous embolization for, 339-344
- Graft-versus-host disease, after allogeneic stem cell transplantation, 550-556
- Granuloma, with skull osteolysis in kidney recipient with cutaneous cryptococcosis, 6:E113
- Growth hormone therapy  
for pediatric chronic kidney disease, S1:68-69  
renal leiomyoma associated with Epstein-Barr virus in pediatric transplant patient, 351-355
- Growth retardation and skeletal maturation delay, in children with CKD, S1:9-10
- Haplotypes,  $\beta$ -fibrinogen, risk of cardiovascular disease in dialysis cohort, 78-85
- HD. *See* Hemodialysis
- Health care disparity, cultural approach for end-of-life planning for long-term dialysis patients and, 111-119
- Health-related quality of life, Medicare reimbursement changes and, 621-627
- Healthy subjects, effect of oral glucose tolerance test on potassium uptake in, 697-705
- Hematocrit, IV iron usage trends in dialysis patients, 650-660
- Hematuria, sudden late onset in previous renal transplant recipient after transplant nephrectomy, 5:E91
- Hemodiafiltration  
mortality risk in ESRD and, 167-168(c)  
vs. hemodialysis and hemofiltration, 787-789(c)
- Hemodialysis (HD). *See also* Maintenance hemodialysis  
access blood flow, optodilutional vs. ultrasound dilution methods, 933-937  
allocation of deceased donor kidneys for transplantation, 949-956  
changes in cardiovascular calcification after parathyroidectomy in ESRD, 464-469  
compared with hemofiltration and hemodiafiltration, 787-789(c)  
effect of oral glucose tolerance test on potassium uptake in, 697-705  
for ESRD  
nephrogenic fibrosing dermatopathy/nephrogenic systemic fibrosis in, 754-759  
valvular calcifications, histological comparison with general population, 86-93
- Genius® Batch Hemodialysis System efficiency with low serum solute concentrations, 5:E95
- high-flux, adequacy of vancomycin dosing regimen in, 681-687
- incident, reuse-associated mortality and, 661-668
- KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925-932
- long-term  
atrial fibrillation prevalence and associated factors in, 897-902  
citrate kinetics in, 903-907  
hospitalization risk, depression and, 642-649  
oxidative metabolism reduction in, 102-110  
malnutrition, prevention of, 371-386  
medication-related problems, 669-680  
morbid obesity and weight change over time effect on cardiovascular survival, 489-500
- mortality  
brachial-ankle pulse wave velocity, ankle-brachial blood pressure index and, 688-696  
mild hyperphosphatemia and, 68-77  
mycotic aneurysm in coronary artery bypass graft of dialysis patient, 962-966  
oligo-anuric patients, spironolactone effect on BP and RAAS in, 94-101  
pretransplantation, effect on allograft and recipient survival, 537-549  
quality of life measured by WHOQOL-BREF(TW), 635-641  
skipped treatments, markers of nutritional nonadherence and survival in, 1107-1116  
soy protein effect on hyperlipidemic and normolipidemic patients, 1099-1106  
techniques and prescription nephrology core curriculum, 976-981  
tunneled catheters in, 501-508
- Hemodialysis catheters. *See* Catheters
- Hemofiltration

- mortality risk calculations, 787(c)  
 risk of mortality in ESRD and, 167-168(c)  
 vs. hemodialysis and hemodiafiltration, 787-789(c)
- Hemoglobin**  
 A<sub>1c</sub>, predisposition to emphysematous pyelonephritis and, 432-439  
 epoetin alfa prescribing patterns in ESRD and, 481-488  
 optimal target, debate over, 970-973  
 in primary glomerular disease, 424-431
- Hemolytic uremic syndrome, with nephrotic syndrome and poststreptococcal glomerulonephritis, 4:E59
- Henoch-Schonlein purpura, followed by proteinuria in child, 1140-1144
- Hepatitis C virus**  
 alloimmune response against GSTT1 in renal transplant recipients, 345-350  
 diagnostic discordance in hemodialysis, 992(letter), 993(reply)  
 glomerulonephritis, without hepatitis C virus in blood, 4:E65  
 identification in maintenance hemodialysis patients, 290-300
- Hepatoblastoma, reversibility of nephromegaly in biliary atresia, 830-836
- Hepatocyte growth factor, degree of nephromegaly in biliary atresia, 830-836
- High-flux membranes, adequacy of vancomycin dosing regimen in hemodialysis, 681-687
- Histoplasmosis, with thrombotic microangiopathy and acute tubular necrosis, 159-162
- HLA haplotype, chronic renal failure with abnormal tubular cells in siblings, 982-987
- HLA mismatch, allocation of deceased donor kidneys for transplantation, 949-956
- Homocysteine, arteriovenous fistula patency and, 993-994(letter)
- Hospitalization, depression and long-term hemodialysis, 642-649
- Hospital resource utilization, uncomplicated acute renal failure and, 1049-1057
- Human T-cell lymphotropic virus type 1-associated myopathy, and nephritis development in SLE patient, 2:E21
- Hypercholesterolemia, cholestyramine effect on renal function, 812-819
- Hyperhomocysteinemia, arteriovenous fistula thrombosis and, 993-994(letter)
- Hyponatremia**  
 etiology and treatment of, 360-361  
 evaluation, water deprivation test not indicated for, 1150(c)
- Hyperoxaluria, increased risk of urolithiasis and nephrocalcinosis in cystic fibrosis and, 440-445
- Hyperphosphatemia, mortality in hemodialysis patients and, 68-77
- Hypersensitivity vasculitis, associated with dapsone, 4:E51
- Hypertension**  
 asymmetric dimethylarginine accumulation and, 186-202  
 early diagnosis of ADPKD using family history analysis and, 415-423
- family history of ESRD, risk perception of kidney disease and, 11-17  
 in individuals at risk for autosomal dominant polycystic kidney disease, 557-559  
 left ventricular hypertrophy in nondiabetic CKD patients, 320-327  
 malignant with intestinal ischemia secondary to juxtaglomerular cell tumor, 957-961  
 management in primary and tertiary care, 18-25  
 and nephrolithiasis in females with high BMI, 263-269  
 with obesity, chronic kidney disease risk and, 587-594  
 in oligo-anuric hemodialysis patients, spironolactone effect on, 94-101
- Hypervolemia, etiology and treatment, 358-359
- Hypocitraturia, urolithiasis and nephrocalcinosis risk in cystic fibrosis and, 440-445
- Hypokalemia, in Chinese peritoneal dialysis patients, 128-135
- Hyponatremia, etiology and treatment of, 359-360
- Hypovolemia, etiology and treatment, 358
- Idiopathic membranous nephropathy treatment strategy, rationale and outline of, 1012-1029
- Immunization, for adult patients with renal disease, 997-1011
- Immunoadsorption therapy, anticardiolipin antibodies during, 446-454
- Immunosuppression**  
 for idiopathic membranous nephropathy, 1012-1029  
 renal leiomyoma associated with Epstein-Barr virus in pediatric transplant patient, 351-355  
 for systemic vasculitis, 173-185
- Infection**  
 complications of *S. aureus* in ESRD patients on hemodialysis, 301-308  
 dialysis access-related, cardiovascular mortality and, 1149  
 mycotic aneurysms in coronary artery bypass graft of dialysis patient, 962-966  
 tunneled catheters in hemodialysis patients, 501-508
- Inflammation**  
 effect of morbid obesity and weight change on cardiovascular survival of hemodialysis patients, 489-500  
 erythropoietin sensitivity in ESRD, influence of body fat mass and leptin levels on, 628-634  
 in ESRD valvular calcifications, compared with general population, 86-93  
 fibrinogen level elevations in ESRD diabetics, 78-85
- Inflammatory markers in diabetic peritoneal dialysis patients, rosiglitazone reduction of, 713-719
- Infliximab, for systemic vasculitis, 173-185
- Insulin**  
 endogenous, effect on potassium uptake in hemodialysis vs. healthy patients, 697-705  
 requirement, of diabetic peritoneal dialysis patients, rosiglitazone reduction of, 713-719
- Intensive care unit, acute renal failure outcome according to RIFLE, 1038-1048
- Interferon  $\gamma$ , expression in peritoneal T-cells in PD-related peritonitis, 328-338



- Interleukin 12, in peritoneal dialysate effluent, peritonitis outcome and, 328–338
- Interleukin 18, in peritoneal dialysate effluent, peritonitis outcome and, 328–338
- Intestinal conduit urinary diversion, urinary tract infections and, 1030–1037
- Intestinal pouch, urinary tract infections and, 1030–1037
- Intracranial granuloma, with skull osteolysis as complication of cutaneous cryptococcosis in kidney transplant recipient, 6:E113
- Iodine 125-iothalamate clearances, in estimating GFR in ill hospitalized patients, 242–252
- Iron, intravenous  
as 2-minute push to CKD patients, 283–289  
usage trends in dialysis patients, 650–660
- Iron deficiency, IV iron sucrose as 2-minute push for CKD patients, 283–289
- Juxtaglomerular cell tumor, secondary intestinal ischemia with malignant hypertension, 957–961
- Karyomegaly, chronic renal failure with abnormal tubular cells in siblings, 982–987
- KDOQI. *See* Kidney Disease Outcomes Quality Initiative
- KEEP (Kidney Early Evaluation Program), annual data report 2005, S3:1–158
- Kidney allocation policy, development of, 974–975
- Kidney Disease Outcomes Quality Initiative (KDOQI)  
epoetin alfa prescribing patterns and hemoglobin outcomes in ESRD, 481–488  
guidelines for bone metabolism and disease in CKD, 925–932
- Kidney disease severity, delay in time receipt of thrombolytic medication, 595–602
- Kidney Early Evaluation Program (KEEP), annual data report 2005, S3:1–158
- Kidney function  
B-type natriuretic peptide and amino-terminal proBNP in CKD and, 610–620  
changes, retinal microvascular abnormalities in elderly and, 214–224  
comprehensive assessment in Gaucher disease, 837–844  
effect of cholesterol reduction with cholestyramine on, 812–819  
estimation in subjects with normal serum creatinine levels, effect of age and BMI on, 233–241  
impairment, recognizing in older patients, 147
- Kidney transplant recipients  
allocation of deceased donor kidneys and, 949–956  
alloimmune response against GSTT1 antigen in, 345–350  
baseline comorbidity in, 136–142  
darboepoetin alfa for anemia during pregnancy, 5:E81  
intracranial granuloma with skull osteolysis as complication of cutaneous cryptococcosis in, 6:E113  
older, 150–151  
pediatric, bone disease in, S1:96–98  
pretransplantation RRT effect on survival, 537–549  
prognosis, baseline comorbidity in, 136–142  
sudden late gross hematuria after transplant nephrectomy, 5:E91
- Kidney volume, sonographic assessment of severity and progression of AKPKD, 1058–1064
- Latent tuberculosis, value of anti-LAM antibody in diagnosis in hemodialysis patients, 706–712
- Leflunomide, for systemic vasculitis, 173–185
- Left ventricular hypertrophy (LVH)  
B-type natriuretic peptide and amino-terminal proBNP in CKD and, 610–620  
erythropoietin therapy for prevention in CKD, 799–811  
in Fabry disease dialysis patients, effect of enzyme replacement therapy on, 120–127  
in nondiabetic predialysis CKD, 320–327  
prediction, in asymptomatic CKD, 35–44  
prevalence in CKD, 1148(c)
- Length of stay  
*Staphylococcus aureus* septicemia in ESRD hemodialysis patients, 301–308  
uncomplicated acute renal failure and, 1049–1057
- Leptin, erythropoietin sensitivity in ESRD and, 628–634
- Leukemia, pseudohyperkalemia due to pneumatic tube transport, 746–748
- Lipids  
reduction  
cardiovascular disease risk, renal transplantation and, 529–536  
with cholestyramine, effect on renal function, 812–819  
outcomes for ACS with chronic renal insufficiency, 845–855  
soy protein effects on hyperlipidemic and normolipidemic hemodialysis patients, 1099–1106
- Lipoprotein, soy protein effects on hyperlipidemic and normolipidemic hemodialysis patients, 1099–1106
- Lithium intoxication therapy, efficiency of Genius® Batch Hemodialysis System for, 5:E95
- Liver transplantation, reversibility of nephromegaly in biliary atresia, 830–836
- LVH. *See* Left ventricular hypertrophy
- Lysosomal storage disease, comprehensive renal function assessment in, 837–844
- Magnetic resonance angiography, atherosclerotic renal artery disease outcome prediction, 1065–1073
- Magnetic resonance imaging, of AKPKD severity and progression, 1058–1064
- Maintenance hemodialysis  
benefits of enteral nutritional support for CKD, 387–405  
identification of HCV in, 290–300  
manganese-induced Parkinsonism and, 749–753
- Males  
allocation of deceased donor kidneys for transplantation, 949–956  
family history of ESRD, risk perception of kidney disease and, 11–17  
natural history of chronic renal failure and, 863–870  
proteinuria and HbG levels in primary glomerular disease, 424–431
- Malnutrition  
effect of weight change on cardiovascular survival of hemodialysis patients, 489–500  
in hemodialysis patients, 371–386



- Malnutrition-inflammation-cachexia syndrome, in HCV infection in maintenance hemodialysis, 290-300
- Manganese, induction of Parkinsonism in maintenance hemodialysis patient, 749-753
- MCKD2 (autosomal dominant medullary cystic kidney disease type 2), novel mutation pattern in, 52-57
- MDRD equation. *See* Modification of Diet in Renal Disease equation
- Medical evaluation, completion rates for renal transplantation, 734-745
- Medicare  
claims data  
de novo congestive heart failure after kidney transplantation, 720-723  
identifying chronic kidney disease from, 225-232  
reimbursement changes, 621-627
- Medication-related problems, in hemodialysis patients, 669-680
- Melphalan, renal response in primary systemic amyloidosis and, 270-277
- Membranoproliferative glomerulonephritis, injury pattern in renal allograft, 573-576
- Mesothelial cells, mesenchymal conversion, high solute transport rate in peritoneal dialysis and, 938-948
- Meta-analysis, benefits of multinutrient support for CKD maintenance dialysis patients, 387-405
- Metabolic acidosis  
acetaminophen-induced and 5-oxoprolinuria acquired in hospital, 143-146  
in pediatric chronic kidney disease, S1:94-95
- Metabolic syndrome, associations with inflammation in CKD, 577-586
- Methanol poisoning, validation of method for predicting required dialysis time for, 509-511
- Methotrexate, for systemic vasculitis, 173-185
- Methylenetetrahydrofolate reductase genotype polymorphism (MTHFR), arteriovenous fistula patency and, 993-994(letter)
- Methylprednisolone, for systemic vasculitis, 173-185
- MGUS (monoclonal gammopathy of undetermined significance), focal and segmental glomerulosclerosis and, 278-282
- Microvasculature retinal abnormalities in elderly, renal function changes and, 214-224
- Mineral metabolism abnormalities, chronic kidney disease mortality and, 455-463
- Minimal change disease  
after allogeneic stem cell transplantation, 550-556  
with stiff-person syndrome, 1:E13
- Modification of Diet in Renal Disease equation (MDRD)  
in estimating GFR in ill hospitalized patients, 242-252  
influence of age and body mass index on normal serum creatinine level subjects, 233-241
- Monoclonal antibodies, for systemic vasculitis, 173-185
- Monoclonal gammopathy of undetermined significance (MGUS), focal and segmental glomerulosclerosis and, 278-282
- Monoclonal light chain fragments in primary systemic amyloidosis, renal response after stem cell transplantation and, 270-277
- Morbidity, vaccines for adult chronic kidney disease patients, 997-1011
- Mortality  
all-cause risk in incident dialysis, KDOQI control guidelines and, 925-932  
chronic kidney disease, relationship of phosphorus and calcium-phosphorus product in, 455-463  
chronic of kidney disease, in elderly diabetics, 406-414  
early initiation of dialysis, effect of comorbidity on, 887-896  
fenoldopam for early acute tubular necrosis and, 26-34  
impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on, 688-696  
mild hyperphosphatemia in hemodialysis patients and, 68-77  
pretransplantation renal replacement therapy effect on, 537-549
- rates  
depression and long-term hemodialysis, 642-649  
natural history of chronic renal failure and, 863-870  
reuse-associated mortality, incident hemodialysis and, 661-668
- risk  
calculations, for hemofiltration, 787(c)  
end-stage renal disease hemodiafiltration and, 167-168(c)  
uncomplicated acute renal failure and, 1049-1057  
vaccines for adult chronic kidney disease patients, 997-1011
- MPO-ANCAs (myeloperoxidase-specific antineutrophil cytoplasmic antibodies), with anti-GBM antibodies in crescentic glomerulonephritis, 253-262
- MTHFR (methylenetetrahydrofolate reductase genotype polymorphism), arteriovenous fistula patency and, 993-994(letter)
- Multidisciplinary predialysis care, effect on survival in CKD, 1088-1098
- Multiple myeloma  
extramedullary hematopoiesis in, 780-786  
focal and segmental glomerulosclerosis and, 278-282
- Musculoskeletal deformities, in children with CKD, S1:10
- Mycophenolate mofetil, for systemic vasculitis, 173-185
- Mycotic aneurysm, in coronary artery bypass graft of dialysis patient, 962-966
- Myeloma cast nephropathy, case report, 780-786
- Myeloperoxidase-specific antineutrophil cytoplasmic antibodies (MPO-ANCAs), with anti-GBM antibodies in crescentic glomerulonephritis, 253-262
- National Health and Nutrition Examination Survey (NHANES III), associations of metabolic syndrome with inflammation in CKD, 577-586
- National Kidney Foundation, KEEP annual data report 2005, S3:1-158
- Natriuretic peptides  
in CKD, relationship to renal function and left ventricular hypertrophy, 610-620  
in ESRD, 1-10  
prediction of cardiac disease in asymptomatic CKD, 35-44
- Neobladder, urinary tract infections and, 1030-1037

- Nephritis development in SLE patient, with human T-cell lymphotropic virus type 1-associated myopathy, 2:E21
- Nephrocalcinosis risk in cystic fibrosis, absorptive hyperoxaluria and, 440-445
- Nephrogenic fibrosing dermopathy  
nephrogenic systemic fibrosis and, 763-765  
with systemic fibrosis, 754-759
- Nephrogenic systemic fibrosis, evolution of nephrogenic fibrosing dermopathy and, 763-765
- Nephrolithiasis, and increased blood pressure in females with high BMI, 263-269
- Nephrologist-preformed urinalysis, vs. clinical laboratory-performed urinalysis, 820-829
- Nephrology clinic, hypertension management in, 18-25
- Nephrology core curriculum  
diabetes and the kidney, 766-773  
disorders of sodium and water, 356-361  
geriatrics, 147-158  
hemodialysis: techniques and prescription, 976-981  
pharmacology, 1129-1139  
tubulointerstitial diseases, 560-572
- Nephromegaly, reversibility in biliary atresia, 830-836
- Nephropathy  
chronic renal failure with abnormal tubular cells in siblings, 982-987  
underusage of ACE inhibitors and ARBs in elderly diabetics, 1080-1087
- Nephroprotection of telmisartan, standard vs. high doses in hypertensive nondiabetic nephropathies, 1074-1079
- Nephrotic syndrome  
minimal change. *See* Minimal change disease  
nonsteroidal anti-inflammatory drug-induced associated with glomerular tip lesion, 4:E55  
with poststreptococcal glomerulonephritis and hemolytic uremic syndrome, 4:E59  
proteinuria and anemia in, 424-431  
and renal failure after allogeneic stem cell transplantation, 550-556  
treatment strategy for idiopathic membranous nephropathy, 1012-1029
- Nesiritide. *See* B-type natriuretic peptide
- NHANES III (National Health and Nutrition Examination Survey III), associations of metabolic syndrome with inflammation in CKD, 577-586
- Nitric oxide impaired synthesis from ADMA accumulation, cardiovascular risk in ESRD, 186-202
- Nonorthotopic urinary diversion, urinary tract infections and, 1030-1037
- Nonsteroidal anti-inflammatory drug-induced nephrotic syndrome, associated with glomerular tip lesion, 4:E55
- Nutrition  
benefits of nutritional support for CKD maintenance dialysis patients, 387-405  
hypokalemia in Chinese peritoneal dialysis patients and, 128-135  
nonadherence and survival in incident hemodialysis patients, 1107-1116  
for older patients, 157
- Obesity  
cardiovascular survival of hemodialysis patients and, 489-500  
chronic kidney disease risk and, 871-880  
with hypertension, chronic kidney disease risk and, 587-594  
nephrolithiasis and increased blood pressure in females, 263-269  
renal function estimation in subjects with normal serum creatinine and, 233-241
- Ochratoxin, CRF with abnormal tubular cells in siblings, 982-987
- Oral glucose tolerance test, serum potassium in hemodialysis patients and, 697-705
- Oral supplementation  
benefits CKD maintenance dialysis patients, 387-405  
manganese-induced Parkinsonism in maintenance hemodialysis patient, 749-753
- Organ involvement, enzyme replacement therapy for Fabry disease and, 120-127
- Osteodystrophy, in pediatric chronic kidney disease  
assessment of, S1:18-22  
surgical management of, S1:23-25
- Osteopontin, in ESRD valvular calcifications, compared with general population, 86-93
- Osteoporosis, in older patients, 155
- Outcome  
baseline comorbidity in renal transplant recipients, 136-142  
economic, of *S. aureus* septicemia in ESRD patients on hemodialysis, 301-308  
identifying chronic kidney disease from Medicare claims data, 225-232  
prediction, in atherosclerotic renal artery disease diagnosed by MRA, 1065-1073
- Overweight, chronic kidney disease risk and, 871-880
- Oxalobacter formigenes*, absorptive hyperoxaluria effect on urolithiasis and nephrocalcinosis risk in cystic fibrosis, 440-445
- Oxidative metabolism, reduction in long-term hemodialysis, 102-110
- 5-Oxoproline, secondary recurrent high anion gap metabolic acidosis, 1:E1
- 5-Oxoprolinuria, with acetaminophen-induced anion gap metabolic acidosis, 143-146
- Parahyperparathyroidism, cinacalcet therapy in predialysis CKD and, 58-67
- Parathyroidectomy  
changes in cardiovascular calcification in ESRD, 464-469  
in pediatric chronic kidney disease, S1:91-93
- Parathyroid hormone, all-cause mortality risk in incident dialysis and, 925-932
- Parkinsonism, manganese-induced in maintenance hemodialysis patient, 749-753
- Patient education, predialysis psychoeducational intervention effect on survival in CKD, 1088-1098
- Patient-nephrologist visits, Medicare reimbursement changes and, 621-627
- Patient opinions, on allocation of deceased donor kidneys for transplantation, 949-956

- PD. *See* Peritoneal dialysis
- Peak bone mass, in CKD, S1:10-11
- Pediatric chronic kidney disease
- active vitamin D therapy in, S1:53-63
  - aluminum overload and toxicity in, S1:70-78
  - aluminum toxicity treatment in, S1:79-86
  - bone disease assessment in, S1:18-22
  - calcium-phosphorus product in, S1:39-47
  - dietary phosphorus intake in, S1:29-31
  - evaluation of calcium and phosphorus metabolism in, S1:12-17
  - growth hormone therapy in, S1:68-69
  - kidney transplant recipients, bone disease in, S1:96-98
  - metabolic acidosis in, S1:94-95
  - parathyroidectomy in, S1:91-93
  - phosphorus dietary intake in, S1:29-31
  - prevention and treatment of vitamin D insufficiency and deficiency in, S1:48-52
  - renal osteodystrophy, surgical management of, S1:23-25
  - serum calcium levels in, S1:39-47
  - target serum phosphorus levels in, S1:26-28
  - treatment of bone disease in, S1:87-90
  - use of phosphate binders in, S1:32-38
- Peer mentoring, effect on end-of-life decision making for long-term dialysis patients, 111-119
- Pelvic insufficiency fracture, autosomal dominant polycystic kidney disease and, 6:E101
- Peritoneal dialysis (PD)
- adult, clinical performance measures for, S2:39-47
  - changes in cardiovascular calcification after parathyroidectomy in ESRD, 464-469
  - endothelial progenitor cells and cardiovascular disease history in ESRD, 520-528
  - high solute transport rate in, mesenchymal conversion of mesothelial cells and, 938-948
  - hypokalemia in Chinese patients, 128-135
  - KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925-932
  - long-term, multiple rare environmental bacteria peritonitis in, 6:E119
  - natriuretic peptides in, 1-10
  - peritonitis, T-cell immune response in, 328-338
  - pretransplantation, effect on allograft and recipient survival, 537-549
  - rosiglitazone reduction of insulin requirements and CRP in diabetic patients, 713-719
  - time profiles of renal clearances for uremic solutes in, 512-519
- Peritoneal transport rate, mesenchymal conversion of mesothelial cells in peritoneal dialysis and, 938-948
- Peritonitis
- CAPD-related, due to *Salmonella enteritidis* in SLE patient, 2:E21
  - with multiple rare environmental bacteria in long-term peritoneal dialysis patient, 6:E119
  - peritoneal-dialysis related, T-cell immune response in, 328-338
  - from *Vibrio vulnificus* after handling seafood in patient receiving CAPD, 5:E87
- Pharmacokinetics, in older patients, 148-149
- Pharmacology
- medication-related problems in hemodialysis patients, 669-680
  - nephrology core curriculum, 1129-1139
- Phosphate binders
- frequency of elevated serum aluminum in adult dialysis patients, 316-319
  - use in pediatric chronic kidney disease, S1:32-38
- Phosphate serum levels, mortality in hemodialysis patients and, 68-77
- Phosphorus
- chronic kidney disease mortality and, 455-463
  - dietary intake in pediatric chronic kidney disease, S1:29-31
  - KDOQI control guidelines, all-cause mortality risk in incident dialysis and, 925-932
  - metabolism, evaluation in pediatric CKD, S1:12-17
- Plasma cell disorders, focal segmental glomerulosclerosis and, 278-282
- Plasma exchange, for systemic vasculitis, 173-185
- Pneumatic tube transport, pseudohyperkalemia in leukemic patient, 746-748
- Population-modeling program, vancomycin dosing regimen adequacy in high-flux hemodialysis, 681-687
- Postinfectious glomerulonephritis
- complicated by hemolytic uremic syndrome and nephrotic syndrome, 4:E59
  - purpura followed by proteinuria in child, 1140-1144
- Potassium, serum
- in Chinese peritoneal dialysis patients, 128-135
  - effect of oral glucose tolerance test hemodialysis patients and, 697-705
  - spironolactone effect on oligo-anuric hemodialysis patients and, 94-101
  - spironolactone reduction of proteinuria in CKD and, 45-51
- Predialysis patients with CKD, cinacalcet therapy for secondary parathyroidism, 58-67
- Predictive value, of identifying chronic kidney disease from Medicare claims data, 225-232
- Preemptive transplantation, medical evaluation completion rates for renal transplantation, 734-745
- Pregnancy, darbepoetin alfa for anemia in renal transplant recipient, 5:E81
- Primary care management, of hypertension, 18-25
- Primary systemic amyloidosis, renal response after high-dose melphalan and stem cell transplantation, 270-277
- Prognosis
- for atherosclerotic renal disease diagnosed by MRA, 1065-1073
  - baseline comorbidity in renal transplant recipients, 136-142
  - for chronic renal failure, 863-870
  - de novo congestive heart failure after kidney transplantation, 720-723
  - in ESRD, natriuretic peptides and, 1-10
  - significance of renal response after high-dose melphalan with STM in primary systemic amyloidosis and, 270-277
- Prognostic markers, for systemic vasculitis, 173-185
- Progression of kidney disease

- in elderly diabetics, 406-414
- preventing in older patients, 147-148
- retinal microvascular abnormalities in elderly and, 214-224
- telmisartan standard vs. high doses in hypertensive non-diabetic nephropathies, 1074-1079
- Proinflammatory cytokines, in HCV infection in maintenance hemodialysis, 290-300
- Propolis, induction of acute renal failure, 6:E125
- Protein-bound solutes, renal clearance time for incident peritoneal dialysis patients, 512-519
- Proteinuria
  - chronic renal failure with abnormal tubular cells in siblings, 982-987
  - early diagnosis of ADPKD using family history analysis and, 415-423
  - in FSGS, plasma cell disorders and, 278-282
  - in primary glomerular disease, 424-431
  - reduction after high-dose melphalan with stem cell transplantation in AL amyloidosis, 270-277
  - spironolactone reduction of, in CKD, 45-51
  - telmisartan standard vs. high doses in hypertensive non-diabetic nephropathies, 1074-1079
- Pseudohyperkalemia, due to pneumatic tube transport in leukemic patient, 746-748
- Psychoeducational predialysis intervention, effect on survival in CKD, 1088-1098
- Purpura, followed by proteinuria in child, 1140-1144
- Pyelonephritis, emphysematous, host and bacterial virulence factors in predisposition of, 432-439
- Pyroglutamic acid, secondary recurrent high anion gap metabolic acidosis, 1:E1
- Pyroglutamic aciduria, acetaminophen-induced anion gap acidosis and, 143-146
- Quality of care
  - Medicare reimbursement changes and, 621-627
  - underusage of ACE inhibitors and ARBs in elderly diabetics, 1080-1087
- Quality of life
  - enzyme replacement therapy for Fabry disease and, 120-127
  - in hemodialysis patients measured by WHOQOL-BREF(TW), 635-641
  - peer mentoring effect on end-of-life decision making for long-term dialysis patients, 111-119
  - skipped treatments and survival in incident hemodialysis patients, 1107-1116
- Race
  - family history of ESRD, risk perception of kidney disease and, 11-17
  - peer mentoring effect on end-of-life decision making for long-term dialysis patients, 111-119
  - skipped treatment, nutritional nonadherence and survival in incident hemodialysis patients, 1107-1116
- Racial disparity
  - medical evaluation completion rates for renal transplantation, 734-745
  - transplantation and, 760-762
- Randomized controlled trials
  - Cochrane Renal Group Report, 774-779
  - effect of cholesterol reduction with cholestyramine on renal function, 812-819
  - erythropoietin therapy for prevention of left ventricular hypertrophy in CKD, 799-811
  - Real-time polymerase chain reaction, in diagnosing chronic GVHD after allogeneic stem cell transplantation, 550-556
  - Referral for dialysis
    - early, predialysis psychoeducational intervention effect on survival in CKD, 1088-1098
    - late, socioeconomic implications of, 881-886
  - Rehabilitation, for older patients, 155-156
  - Relative risk for mortality, mild hyperphosphatemia in hemodialysis and, 68-77
  - Renal artery atherosclerosis, diagnosed by MRA, outcome prediction for, 1065-1073
  - Renal clearance time, of uremic solutes for incident peritoneal dialysis patients, 512-519
  - Renal hypersensitivity vasculitis, dapson-associated, 4:E51
  - Renal insufficiency, anticardiolipin antibodies during immunoadsorption therapy and, 446-454
  - Renal leiomyoma, associated with Epstein-Barr virus in pediatric transplant patient, 351-355
  - Renal replacement therapy (RRT). *See also* Hemodialysis; Peritoneal dialysis
    - for acute renal failure, erythropoietin and, 791-798
    - for ESRD in France in 2003, prevalence of, 309-325
    - late referral, socioeconomic implications of, 881-886
    - natural history of chronic renal failure and, 863-870
    - predialysis psychoeducational intervention effect on survival in CKD, 1088-1098
    - pretransplantation, effect on allograft and recipient survival, 537-549
  - Renal transplantation. *See also* Kidney transplant recipients
    - allocation of deceased donor kidneys, 949-956
    - cardiovascular disease risk and, 529-536
    - darbepoetin alfa for anemia during pregnancy, 5:E81
    - de novo congestive heart failure after, 720-723
    - medical evaluation completion rates for, 734-745
    - for older donors and recipients, 150-151
    - pediatric recipient, Epstein-Barr virus associated with renal leiomyoma in, 351-355
    - pretransplantation RRT effect on allograft and recipient survival, 537-549
    - randomized controlled trials, Cochrane Renal Group Report on, 774-779
    - sudden late gross hematuria in recipient after transplant nephrectomy, 5:E91
    - vaccines for adult chronic kidney disease patients, 997-1011
    - waiting list for Aboriginal hemodialysis patients, 1117-1123
  - Renin-angiotensin-aldosterone system
    - in oligo-anuric hemodialysis patients, spironolactone effect on, 94-101
    - telmisartan standard vs. high doses in hypertensive non-diabetic nephropathies, 1074-1079
  - Renovascular disease, in older patients, 149
  - Residual renal function, renal clearance time of uremic solutes for incident peritoneal dialysis patients, 512-519

- Resistive index, relationship with arteriosclerosis in damaged kidneys, 603-609
- Retina microvascular abnormalities in elderly, renal function changes and, 214-224
- RIFLE classification, acute renal failure outcome in ICU, 1038-1048
- Risk perception, of kidney disease, 11-17
- Rosiglitazone, insulin requirement and CRP levels in diabetic PD patients, 713-719
- Salmonella enteritidis* CAPD-related peritonitis, in SLE patient, 2:E21
- Salt and water handling, in older patients, 150
- SAPS II (Simplified Acute Physiology Score II), acute renal failure outcome in ICU, 1038-1048
- Screening  
for autosomal dominant polycystic kidney disease in non-symptomatic patients, 557-559  
validation of depression tool for dialysis patients, 919-924
- Senescence, asymmetric dimethylarginine accumulation and, 186-202
- Sensitivity of identifying chronic kidney disease from Medicare claims data, 225-232
- Septicemia, clinical and economic outcomes in ESRD patients on hemodialysis, 301-308
- Sex. *See* Females; Males
- Sexual function, asymmetric dimethylarginine accumulation and, 186-202
- Simplified Acute Physiology Score II (SAPS II), acute renal failure outcome in ICU, 1038-1048
- Sirolimus, thrombotic microangiopathy in patients receiving marginal kidneys, 1124-1128
- Sjögren syndrome, with long-standing tubulointerstitial nephritis, secondary renal amyloidosis and, 5:E75
- SLE. *See* Systemic lupus erythematosus
- Smooth muscle tumor, with Epstein-Barr virus in pediatric kidney transplant recipient, 351-355
- Socioeconomic status  
area level, chronic progressive kidney disease and, 203-213  
late referral for renal replacement therapy and, 881-886
- Sodium balance, disorders of, 358-359
- Sodium citrate  
CVVH with citrate-based replacement fluid, 908-918  
kinetics in long-term hemodialysis therapy, 903-907
- Soy protein, effect on hyperlipidemic and normolipidemic hemodialysis patients, 1099-1106
- Specificity of identifying chronic kidney disease, from Medicare claims data, 225-232
- Spironolactone  
in oligo-anuric hemodialysis patients, effect on BP and RAAS, 94-101  
reduction of proteinuria in CKD, 45-51
- Stable isotope-labeled bicarbonate, measurement of whole-body bicarbonate production in hemodialysis patients, 102-110
- Staphylococcus aureus* septicemia, clinical and economic outcomes in ESRD patients on hemodialysis, 301-308
- Stem cell transplantation, renal response in primary systemic amyloidosis and, 270-277
- Stiff-person syndrome, with minimal change nephrotic syndrome, 1:E13
- Substance abuse, skipped treatments and survival in incident hemodialysis patients, 1107-1116
- Survival analysis  
of ACS with chronic renal insufficiency, 845-855  
natural history of chronic renal failure, 863-870  
baseline comorbidity in renal transplant recipients, 136-142  
renal response after high-dose melphalan with stem cell transplantation in primary systemic amyloidosis and, 270-277
- Systemic fibrosis, with nephrogenic fibrosing dermopathy, 754-759
- Systemic lupus erythematosus (SLE)  
anticardiolipin antibodies during immunoabsorption therapy, 446-454  
CAPD-related peritonitis due to *Salmonella enteritidis* in, 2:E21  
nephritis development in patient with human T-cell lymphotropic virus type 1-associated myopathy, 2:E21
- Systemic vasculitis, new therapeutic alternatives for, 173-185
- Tamm-Horsfall protein, evidence of a fourth calcium-binding epidermal growth factor-like domain in, 52-57
- Taq-Man quantitative polymerase chain reaction, in diagnosing chronic GVHD after allogeneic stem cell transplantation, 550-556
- T-cell immune response, in peritoneal dialysis-related peritonitis, 328-338
- Telmisartan, long-term renoprotective effects of standard vs. high doses in hypertensive nondiabetic nephropathies, 1074-1079
- Tertiary care management, of hypertension, 18-25
- Thromboembolic complications, anticardiolipin antibodies during immunoabsorption therapy and, 446-454
- Thrombolysis, outcomes for acute coronary syndrome with chronic renal insufficiency, 845-855
- Thrombolytic medication, delay in time receipt among Medicare patients with kidney disease, 595-602
- Thrombotic microangiopathy  
with disseminated histoplasmosis and acute tubular necrosis, 159-162  
in marginal kidneys after sirolimus use, 1124-1128
- Time profiles, of renal clearances for uremic solutes in incidental peritoneal dialysis, 512-519
- Transcatheter vascular embolization, for graft intolerance syndrome, incidence/efficacy of, 339-344
- Transcription-mediated amplification, identification of HCV in maintenance hemodialysis patients, 290-300
- Transforming growth factor  $\beta 1$ , degree of nephromegaly in biliary atresia, 830-836
- Transfusion requirements for ARF patients, effect of erythropoietin on, 791-798
- Transplantation. *See also* Renal transplantation  
liver, reversibility of nephromegaly in biliary atresia, 830-836  
racial disparities and, 760-762



- Triglycerides, soy protein effects on hyperlipidemic and normolipidemic hemodialysis patients, 1099-1106
- Trimethoprim-sulfamethoxazole, for systemic vasculitis, 173-185
- Troponin, in predicting coronary disease in asymptomatic CKD, 35-44
- Tuberculin skin test, diagnosis of latent tuberculosis in hemodialysis, 706-712
- Tuberculosis, value of anti-LAM antibody in diagnosis in hemodialysis patients, 706-712
- Tubular function, comprehensive assessment in Gaucher disease, 837-844
- Tubulointerstitial diseases, nephrology core curriculum, 560-572
- Tubulointerstitial nephritis  
and Fanconi syndrome in primary biliary cirrhosis, 3:E41  
in Sjögren syndrome, secondary renal amyloidosis and, 5:E75
- Tubulointerstitium, relationship of resistive index to atherosclerosis in, 603-609
- Tunneled catheters, in hemodialysis patients, 501-508
- Ultrasonography  
assessment of severity and progression of AKPKD, 1058-1064  
relationship of resistive index with arteriosclerosis in damaged kidneys, 603-609
- Uremic toxin, as cardiovascular risk factor in ESRD, 186-202
- Ureterosigmoidostomy, urinary tract infections and, 1030-1037
- Urinalysis, performed by nephrologist vs. clinical laboratory, 820-829
- Urinary diversion, urinary tract infections and, 1030-1037
- Urinary tract infections, in urinary diversion patients, 1030-1037
- Urinary tract obstruction, predisposition to emphysematous pyelonephritis, 432-439
- Urolithiasis risk in cystic fibrosis, absorptive hyperoxaluria and, 440-445
- Uromodulin disorders, novel mutation pattern in, 52-57
- Vaccines, for adult patients with renal disease, 997-1011
- Validation, of hemodialysis patient quality of life measured by WHOQOL-BREF(TW), 635-641
- Vancomycin dosing regimen, adequacy in high-flux hemodialysis, 681-687
- Vascular access  
blood flow, comparison of optodilutional and ultrasound dilution methods, 933-937  
blood flow evaluation by optodilutional vs. ultrasound dilution methods, 933-937  
dialysis access-related infections, cardiovascular mortality and, 1149  
shorter unassisted patency after angioplasty in women, 167(c)  
tunneled catheters in hemodialysis patients, 501-508
- Vascular dementia, in older patients, 153-154
- Vascular endothelial growth factor (VEGF), mesenchymal conversion of mesothelial cells in peritoneal dialysis and, 938-948
- Vasculature  
calcifications in ESRD, changes after parathyroidectomy, 464-469  
relationship of resistive index to atherosclerosis in damaged kidneys, 603-609
- Vibrio vulnificus* peritonitis, after handling seafood in patient receiving CAPD, 5:E87
- Virulence factors, predisposition to emphysematous pyelonephritis, 432-439
- Vitamin D  
active therapy in pediatric chronic kidney disease, S1:53-63  
insufficiency/deficiency, prevention and treatment in pediatric chronic kidney disease, S1:48-52
- Volume status in ESRD, natriuretic peptides and, 1-10
- Waiting time for transplantation, allocation of deceased donor kidneys and, 949-956
- Water balance  
disorders of, 359-361  
physiology of, 357-358
- Water deprivation test, for hypernatremia evaluation, 1150(c)
- Weight loss, cardiovascular survival of hemodialysis patients and, 489-500
- World Health Organization Quality-of-Life Questionnaire Brief Taiwanese version, validation of, 635-641



